Screener
Medpace Holdings, Inc. MEDP Direct Costs — Total direct costs
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Medpace Holdings, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DirectOperatingCosts.
The source filing: Medpace Holdings, Inc.’s 10-Q, filed July 23, 2026.
- Filed
- Jul 23, 2026, 4:03 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001668397-26-000025
| (Amounts in thousands, except per share amounts) | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Revenue, net (includes $4.7 million and $16.9 million with related parties for the three months ended June 30, 2026 and 2025, respectively, and $12.0 million and $30.7 million with related parties for the six months ended June 30, 2026 and 2025, respectively) | $707,331 | $603,311 | $1,413,935 | $1,161,881 |
| Operating expenses: | ||||
| Direct service costs, excluding depreciation and amortization | 202,555 | 185,826 | 400,829 | 363,642 |
| Reimbursed out-of-pocket expenses | 303,139 | 237,472 | 615,143 | 439,876 |
| Total direct costs | 505,694 | 423,298 | 1,015,972 | 803,518 |
| Selling, general and administrative | 48,103 | 46,664 | 96,020 | 104,561 |
| Depreciation | 6,555 | 6,777 | 13,306 | 13,471 |
| Amortization | 155 | 237 | 310 | 473 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Medpace Holdings, Inc.'s direct costs — total direct costs?
- Medpace Holdings, Inc. (MEDP) reported direct costs — total direct costs of $202.56M in Q2 2026.
- How has Medpace Holdings, Inc.'s direct costs — total direct costs changed year-over-year?
- Medpace Holdings, Inc.'s direct costs — total direct costs increased by 9.0% year-over-year, from $185.83M to $202.56M.
- What is the long-term trend for Medpace Holdings, Inc.'s direct costs — total direct costs?
- Over 4 years (2021 to 2025), Medpace Holdings, Inc.'s direct costs — total direct costs has grown at a 13.5% compound annual growth rate (CAGR), from $441.09M to $732.13M.
- What does direct costs — total direct costs mean?
- This metric represents the aggregate expenses directly attributable to the delivery of clinical research and development services. It encompasses the primary costs required to execute client projects, including personnel, site management, and specialized laboratory activities. Monitoring this total provides visibility into the variable cost structure required to support the company's revenue-generating operations.
Ask your AI about Medpace Holdings, Inc.'s direct costs — total direct costs.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude